MonoGen halts commercial ops, chops staff

Cut off from raising funds by a roiled public market, MonoGen announced that it is halting commercial operations and laying off 75 percent of its work force. Piper Jaffray has been brought in to assess the remaining financial alternatives for the diagnostics company.

"It is with great disappointment that we find it necessary to take this strong action at this time," said Ted S. Geiselman, MonoGen's CEO. "Despite our significant and thorough efforts seeking additional investment capital, adverse financial market conditions in conjunction with increased challenges on the commercial front have made raising additional capital unfeasible.

- check out the press release

Related Articles:
Scientists leave biotech for clean tech
Congress extends R&D tax credit in bailout
Financial crisis clouds the future of biopharma
Economy catches up with biotech investing
Despite layoffs, scientists in high demand